Olanzapine and warfarin drug interaction

J. F. Maya, John Callaghan, R. F. Bergstrom, B. J. Cerimele, K. Kassahun, E. H. Nyhart, D. C. Brater

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

An interaction study in 15 males was conducted between olanzapine (OL), an atypical antipsychotic, and warfarin (W) as a 3-way randomized crossover. The S-isomer of W is a probe for CYP2C9 metabolism. Each subject ingested 10mg OL or 20mg (R/S) W alone, and OL+W combination (OL+) as single doses (10 day washout interposed). OL+ did not potentiate adverse events of OL or W or anticoagulant effects of W. Stereo specific assays for RW and SW (HPLC-UV) and OL (HPLC-EC) were done. RW, SW and OL noncompartmental pharmacokinetics (PK) were assessed. Statistical evaluation by ANOVA for crossover design showed no significant (p>0.05) differences between OL or W versus OL+. PK Variables OL OL+ RW RW+ SW SW+ Cmax ng/mL 10.7 9.5 1280 1210 1330 1250 T1/2 hr 27.9 30.0 37.7 39.0 131.3 31.3 AUCμg×hr/mL .377 .353 48.5 47.4 36.3 35.8 CL/FF L/hr 29.8 30.9 0.21 0.22 0.28 0.29 Vβ/FF L 1150 1300 11.4 12.0 12.6 12.7 W PK were unaffected by concomitant OL and vice versa. OL does not inhibit CYP2C9.

Original languageEnglish
Pages (from-to)182
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume61
Issue number2
StatePublished - 1997

Fingerprint

olanzapine
Warfarin
Drug Interactions
Pharmacokinetics
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology

Cite this

Maya, J. F., Callaghan, J., Bergstrom, R. F., Cerimele, B. J., Kassahun, K., Nyhart, E. H., & Brater, D. C. (1997). Olanzapine and warfarin drug interaction. Clinical Pharmacology and Therapeutics, 61(2), 182.

Olanzapine and warfarin drug interaction. / Maya, J. F.; Callaghan, John; Bergstrom, R. F.; Cerimele, B. J.; Kassahun, K.; Nyhart, E. H.; Brater, D. C.

In: Clinical Pharmacology and Therapeutics, Vol. 61, No. 2, 1997, p. 182.

Research output: Contribution to journalArticle

Maya, JF, Callaghan, J, Bergstrom, RF, Cerimele, BJ, Kassahun, K, Nyhart, EH & Brater, DC 1997, 'Olanzapine and warfarin drug interaction', Clinical Pharmacology and Therapeutics, vol. 61, no. 2, pp. 182.
Maya JF, Callaghan J, Bergstrom RF, Cerimele BJ, Kassahun K, Nyhart EH et al. Olanzapine and warfarin drug interaction. Clinical Pharmacology and Therapeutics. 1997;61(2):182.
Maya, J. F. ; Callaghan, John ; Bergstrom, R. F. ; Cerimele, B. J. ; Kassahun, K. ; Nyhart, E. H. ; Brater, D. C. / Olanzapine and warfarin drug interaction. In: Clinical Pharmacology and Therapeutics. 1997 ; Vol. 61, No. 2. pp. 182.
@article{cf6debe117134cf2a3ec9fd8fbcd6c4f,
title = "Olanzapine and warfarin drug interaction",
abstract = "An interaction study in 15 males was conducted between olanzapine (OL), an atypical antipsychotic, and warfarin (W) as a 3-way randomized crossover. The S-isomer of W is a probe for CYP2C9 metabolism. Each subject ingested 10mg OL or 20mg (R/S) W alone, and OL+W combination (OL+) as single doses (10 day washout interposed). OL+ did not potentiate adverse events of OL or W or anticoagulant effects of W. Stereo specific assays for RW and SW (HPLC-UV) and OL (HPLC-EC) were done. RW, SW and OL noncompartmental pharmacokinetics (PK) were assessed. Statistical evaluation by ANOVA for crossover design showed no significant (p>0.05) differences between OL or W versus OL+. PK Variables OL OL+ RW RW+ SW SW+ Cmax ng/mL 10.7 9.5 1280 1210 1330 1250 T1/2 hr 27.9 30.0 37.7 39.0 131.3 31.3 AUCμg×hr/mL .377 .353 48.5 47.4 36.3 35.8 CL/FF L/hr 29.8 30.9 0.21 0.22 0.28 0.29 Vβ/FF L 1150 1300 11.4 12.0 12.6 12.7 W PK were unaffected by concomitant OL and vice versa. OL does not inhibit CYP2C9.",
author = "Maya, {J. F.} and John Callaghan and Bergstrom, {R. F.} and Cerimele, {B. J.} and K. Kassahun and Nyhart, {E. H.} and Brater, {D. C.}",
year = "1997",
language = "English",
volume = "61",
pages = "182",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Olanzapine and warfarin drug interaction

AU - Maya, J. F.

AU - Callaghan, John

AU - Bergstrom, R. F.

AU - Cerimele, B. J.

AU - Kassahun, K.

AU - Nyhart, E. H.

AU - Brater, D. C.

PY - 1997

Y1 - 1997

N2 - An interaction study in 15 males was conducted between olanzapine (OL), an atypical antipsychotic, and warfarin (W) as a 3-way randomized crossover. The S-isomer of W is a probe for CYP2C9 metabolism. Each subject ingested 10mg OL or 20mg (R/S) W alone, and OL+W combination (OL+) as single doses (10 day washout interposed). OL+ did not potentiate adverse events of OL or W or anticoagulant effects of W. Stereo specific assays for RW and SW (HPLC-UV) and OL (HPLC-EC) were done. RW, SW and OL noncompartmental pharmacokinetics (PK) were assessed. Statistical evaluation by ANOVA for crossover design showed no significant (p>0.05) differences between OL or W versus OL+. PK Variables OL OL+ RW RW+ SW SW+ Cmax ng/mL 10.7 9.5 1280 1210 1330 1250 T1/2 hr 27.9 30.0 37.7 39.0 131.3 31.3 AUCμg×hr/mL .377 .353 48.5 47.4 36.3 35.8 CL/FF L/hr 29.8 30.9 0.21 0.22 0.28 0.29 Vβ/FF L 1150 1300 11.4 12.0 12.6 12.7 W PK were unaffected by concomitant OL and vice versa. OL does not inhibit CYP2C9.

AB - An interaction study in 15 males was conducted between olanzapine (OL), an atypical antipsychotic, and warfarin (W) as a 3-way randomized crossover. The S-isomer of W is a probe for CYP2C9 metabolism. Each subject ingested 10mg OL or 20mg (R/S) W alone, and OL+W combination (OL+) as single doses (10 day washout interposed). OL+ did not potentiate adverse events of OL or W or anticoagulant effects of W. Stereo specific assays for RW and SW (HPLC-UV) and OL (HPLC-EC) were done. RW, SW and OL noncompartmental pharmacokinetics (PK) were assessed. Statistical evaluation by ANOVA for crossover design showed no significant (p>0.05) differences between OL or W versus OL+. PK Variables OL OL+ RW RW+ SW SW+ Cmax ng/mL 10.7 9.5 1280 1210 1330 1250 T1/2 hr 27.9 30.0 37.7 39.0 131.3 31.3 AUCμg×hr/mL .377 .353 48.5 47.4 36.3 35.8 CL/FF L/hr 29.8 30.9 0.21 0.22 0.28 0.29 Vβ/FF L 1150 1300 11.4 12.0 12.6 12.7 W PK were unaffected by concomitant OL and vice versa. OL does not inhibit CYP2C9.

UR - http://www.scopus.com/inward/record.url?scp=0009743787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0009743787&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 182

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -